Cardiovascular Business (2/27) reported “an analysis of the 2015 SPRINT trial has found that, if participants continued taking their antihypertensive medications for the remainder of their lives, intensive blood pressure control could add between six months and three years to their lifespan.” Moreover, “the effect was most pronounced in patients who started intensive BP control at a younger age.” Specifically, “the study’s investigators concluded that, over time, reducing BP lower than normal targets could reduce overall death rates by 27% for adults at an increased risk for heart trouble,” according to findings published in JAMA Cardiology.
HealthDay (2/28, Preidt) reported the “landmark trial published in 2015 showed that intensive blood pressure control could reduce overall death rates by 27% for adults with high heart disease risk, but patients might not fully understand how that affects them, the study authors noted,” so they “decided to reframe the findings to be more meaningful for patients.” Their “analysis did not account for potential risks associated with intensive blood pressure control, such as kidney injury and low blood pressure, the study authors noted.”
- ACC CV news digest
No comments:
Post a Comment